menu menu_open
Brazil
Logomarca do periódico: Hematology, Transfusion and Cell Therapy

Open-access Hematology, Transfusion and Cell Therapy

Publication of: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
Area: Health Sciences ISSN printed version: 2531-1379
ISSN online version: 2531-1387 Previous title Revista Brasileira de Hematologia e Hemoterapia
launch Submission of manuscripts info About the journal people Editorial Board help_outline Instructions to authors article Política editorial
home Journal homepage
All issues « Previous issue Current issue Next issue »
Search show_chart Metrics
home All Search Metrics
navigate_before current navigate_next
  1. navigate_before Journals
  1. home
  2. Journals
  3. Hematology, Transfusion and Cell Therapy
  4. About the journal

ABOUT THE JOURNAL

 

The journal Hematology, Transfusion and Cell Therapy (HTCT) is an open-access, quarterly scientific publication of continuous modality published by the Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH), Italo-Brazilian Association of Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG) and Brazilian Society of Pediatric Oncology (SOBOPE).

The abbreviation of its title, Hematol., Transfus Cell Ther., should be used as footnotes or in references etc. when citing articles published in the journal                          

Editors

Eduardo Magalhães Rego

Erich Vinícius de Paula

 

 

Brief Background

 

Hematology, Transfusion and Cell Therapy (HTCT) succeeded the Brazilian Journal of Hematology and Hemotherapy (ISSN 1516-8484), which, in turn, succeeded the Bulletin of the Brazilian Society of Hematology and Hemotherapy (ISSN 0102-7662), published from 1973 to 1998, with 179 issues in 20 volumes.

Previous Editors

Antonio P. Capanema (1973-1981)

Milton A. Ruiz (1981-1990)

Carlos S. Chiattone (1991-1994)

Milton A. Ruiz (1995-2014)

Fernando F. Costa (2015-2022)

 

 

Our mission

 

To promote the development of the areas of Hematology, Transfusion and Cell Therapy, publishing original research articles, revisions, debates, commentaries and other scientifical contributions related to these areas.

 

 

Open Science Compliance

 

This journal follows the Gold Open Access model.

Hematology, Transfusion and Cell Therapy is committed to the principles of open science, promoting transparency, accessibility and collaboration in scientific communication. Below are some important practices adopted by the journal:

  1. Open Science Policy: Our editorial policy reflects our commitment to open science, encouraging practices that ensure transparency and free access to scientific information.
  2. Preprint Manuscripts: We accept manuscripts that have been deposited on recognized preprint servers, promoting the rapid dissemination and broad discussion of research results.
  3. Research Data: Although not yet a mandatory requirement, we strongly encourage authors to cite and reference all pertinent research data, promoting scientific integrity and reproducibility.
  4. Peer Review: The journal uses a double-blind peer review system, ensuring a fair and transparent evaluation process. We are open to practices that promote constructive discussions between reviewers and authors.
 

 

Ethics in Publication

 

Hematology, Transfusion and Cell Therapy (HTCT) is based on the main ethical practices of COPE. All manuscripts, in order to be evaluated, must submit the following documentation:

  • Conflict of interest: situations that may inappropriately influence the development or conclusions of the work should be mentioned, such as equity interest in companies producing the drugs or equipment mentioned or used in the work, as well as their competitors. Financial assistance received, consultancy, subordination relationships at work, etc. are also considered sources of conflict.
  • Approval of the study by a Research Ethics Committee recognized by a National Research Ethics Committee (such as CONEP in Brazil);
  • Articles dealing with clinical research involving human beings must include in the Methods section a statement that the study subjects signed an informed consent form. The authors must also inform that the research was conducted in accordance with the Declaration of Helsinki revised in 2008;
  • In the case of works involving animal experimentation, authors must indicate in the Methods section that the standards contained in the CIOMS (Council for International Organization of Medical Sciences), the Ethical Code for Animal Experimentation  - WHO Chronicle 1985; 39(2):51-6 were followed and they must complete the ‘Declaration of Human and Animal Rights’.
  • All randomized controlled trials and clinical trials submitted for publication must be registered in a clinical trials database. This is a guideline from the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and the International Committee of Medical Journal Editors (ICMJE). Registration instructions are available in the ICMJE website and registration can be done in the National Library of Medicine clinical trials database.
 

 

Focus and Scope

 

Hematology, Transfusion and Cell Therapy (HTCT) aims to record and promote the scientific development of Hematology, Transfusion and Cell Therapy and related areas.

 

 

Digital Preservation

 

This journal follows the standards defined in the Digital Preservation Policy of the SciELO Program.

 

 

Indexing Sources

   

 

Bibliographic Journal Information

 
  • Journal title: Hematology, Transfusion and Cell Therapy
  • Abbreviated title: Hematol., Transfus. Cell Ther.
  • Publication by: Elsevier
  • Frequency: Quarterly
  • Publication modality: Continuous publication
  • Year of creation of the journal: 2018
  • Previous title: Revista Brasileira de Hematologia e Hemoterapia
 

 

Websites and Social Media

   

 

EDITORIAL POLICY

 

Preprints

 

Hematology, Transfusion and Cell Therapy accepts preprints as an important practice in open science, allowing the rapid dissemination and discussion of research results.

According to SciELO guidelines:

  • Acceptance of Preprint Manuscripts: We accept submissions of manuscripts that have been previously deposited on recognized preprint servers. Authors are encouraged to mention the preprint deposit in their submission, ensuring transparency in the process.
  • Deposit on Preprint Servers: The journal may optionally deposit articles already approved on preprint servers such as the SciELO preprint repository and Lume during the editing process of the final version, expanding access and visibility of research.

Preprints should be clearly marked as such, for example by including the word preprint or the name of the preprint server as part of the reference. The DOI of the preprint should also be provided.

After approval, a DOI (Digital Object Identifier) ​​will be assigned to the article, guaranteeing a permanent link and facilitating indexing and citation.

 

 

Peer Review Process

 

Hematology, Transfusion and Cell Therapy (HTCT) uses double-blind peer reviewing: all manuscripts, after an initial assessment by the Editors, will be forwarded for evaluation by at least two peer reviewers, with anonymity guaranteed throughout the entire evaluation process. Suggested changes will be sent to the authors for them to either include in the text or justify their decision to keep the original text. The authors are solely responsible for the concepts expressed in the articles.

Papers must be submitted exclusively to Hematology, Transfusion and Cell Therapy (ISSN 2531-1379). Simultaneous submission to another journal is prohibited.

 

 

Open Data

 

Articles published in Hematology, Transfusion and Cell Therapy (HTCT) may link their research data to data repositories such as SciELO Data, allowing open access and a better understanding of the research described. More information is available on the journal's official website.

This is related to ‘the sharing of data, codes, methods and other materials used and resulting from research that generally underlie the texts of articles published by journals’.

 

 

Fees

 

The journal Hematology, Transfusion and Cell Therapy (HTCT) does not charge any fees for submission or publication.

 

 

Ethics and Misconduct, Correction and Retraction Policy

 

Cases of author misconduct, such as fraudulent manipulation or plagiarism, will be treated as scientific ethical abuse. The journal uses originality verification tools, such as Crossref Similarity Check, to ensure compliance with ethical standards. Any suspected misconduct should be formally reported to the Editor-in-Chief, who will take appropriate action in accordance with the journal's policies and established ethical guidelines.

Errata: Requests for errata and retractions must be formally forwarded to the Editor-in-Chief of the journal.

 

 

Policy on Conflict of Interest

 

Conflict of interest: situations that may inappropriately influence the development or conclusions of the work, such as equity interest in companies producing the drugs or equipment mentioned or used in the work, as well as of their competitors, must be mentioned. Grants received, consultancies, subordination relationships at work, etc. are also considered sources of conflict. Conflicts of interest may also be personal, commercial, political, academic or financial in nature, and may occur when authors, reviewers or editors have interests that may influence the preparation or evaluation of manuscripts.

 

 

Adoption of Similarity Software

 

The submitted articles are checked for originality and possible plagiarism using the Crossref Similarity Check tool.

 

 

Adoption of Software Using Artificial Intelligence Resources

 

The Hematology, Transfusion and Cell Therapy journal recognizes the growing role of artificial intelligence (AI) tools in scientific research and communication of results. In accordance with SciELO guidelines:

Acceptance of AI and Chatbots: The use of AI tools, including chatbots, is accepted to assist in specific processes of scientific research. However, authors must ensure that the use of these tools is clearly mentioned in the manuscript, ensuring transparency and scientific integrity.

Allowed use cases:

  • Data Analysis: AI software can be used to perform complex data analysis, as long as the methods and tools employed are clearly described in the methods section of the manuscript.
  • Writing and Proofreading Assistance: AI tools can be used to support writing and grammatical proofreading of the text. However, responsibility for the accuracy, originality, and integrity of the final content remains solely with the authors.
  • Image Generation or Data Visualizations: AI tools can be used to create data visualizations, as long as the source and software used are properly credited.
  • Transparency and Declaration: Any use of AI must be declared in the manuscript submission, specifying the software or tool used and the purpose of its use.
 

 

Gender and Sex Issues

 

Hematology, Transfusion and Cell Therapy (HTCT) reinforces the importance of integrating sex-based analyses in research, clearly defining the terms ‘sex’ and ‘gender’ to avoid ambiguity. Inclusive language that recognizes diversity and promotes equality is recommended. Authors should explicitly state the definitions of sex and gender applied in their studies to ensure accuracy and rigor. Inclusion of sex- and gender-based analysis is seen as essential for the relevance and quality of scientific research. Authors can consult the Sex and Gender Equity in Research (SAGER) guidelines.

 

 

Ethics Committee

   

 

Copyright

 

Authors license their works under the Creative Commons Attribution CC BY 4.0 license, which allows articles to be reused and distributed without restriction, provided the original work is properly cited. Authors retain the copyright of the published articles, while the journal holds the right of first publication.

 

 

Intellectual Property and Terms of Use

 

All articles published by Hematology, Transfusion and Cell Therapy (HTCT) are licensed under the Creative Commons Attribution CC BY 4.0 license, except where otherwise specified. This means they can be reused and distributed without restriction, provided the original work is properly cited. Authors retain copyright of published articles, while the journal retains the right of first publication.

The authors are solely responsible for the concepts expressed in the articles. It is the authors' responsibility to obtain a letter of permission to reproduce any material included in the work that may have been published previously.

Hematology, Transfusion and Cell Therapy encourages authors to self-archive their accepted manuscripts by publishing them on personal blogs, institutional repositories, and academic social media, as well as posting them on their personal social media, provided that full citation to the journal website version is included.

 

 

Sponsors and Promotion Agencies

 
  • Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (Brazilian Association of Hematology, Hemotherapy and Cell Therapy)

 

EDITORIAL BOARD

 

Editor-in-Chief

   

 

Deputy Editor

   

 

Associate Editors

   

 

INSTRUCTIONS TO AUTHORS

 

The journal Hematology, Transfusion and Cell Therapy (HTCT) is an open-access, quarterly scientific publication of continuous modality published by the Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH), Italo-Brazilian Association of Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG) and Brazilian Society of Pediatric Oncology (SOBOPE).

The submission of the manuscript in English must be done electronically on the website of the journal Hematology, Transfusion and Cell Therapy.

It is the authors' responsibility to obtain a letter of permission to reproduce any material included in the work, which may have been published previously.

The editor may publish manuscripts that do not comply exactly with these instructions after careful evaluation, always focused on the interest and progress of Hematology, Transfusion and Cell Therapy (HTCT).

Hematology, Transfusion and Cell Therapy is committed to the principles of open science, promoting transparency, accessibility and collaboration in scientific communication. Below are some important practices adopted by the journal:

  1. Open Science Policy: Our editorial policy reflects our commitment to open science, encouraging practices that ensure transparency and free access to scientific information.
  2. Preprint Manuscripts: We accept manuscripts that have been deposited on recognized preprint servers, promoting the rapid dissemination and broad discussion of research results.
  3. Research Data: Although not yet a mandatory requirement, we strongly encourage authors to cite and reference all pertinent research data, promoting scientific integrity and reproducibility.
  4. Peer Review: The journal uses a double-blind peer review system, ensuring a fair and transparent evaluation process. We are open to practices that promote constructive discussions between reviewers and authors.
 

 

Technical requirements

 

1. Identification of the manuscript

  • Title of the article in English, which should be concise but informative;
  • Full name of each author, without abbreviations; it is recommended that every author has an ORCID ID to ensure correct attribution of their works and academic contributions.
  • Institutional affiliation (full name of the institution to which authors are affiliated);
  • Name, address, telephone number and e-mail of the corresponding author;
  • Sources of research funding

2. Abstract

The abstract should have a maximum of 250 words. For original articles, it should be structured, highlighting the introduction, the objective(s) of the study, method(s), result(s) and conclusion(s). For the other categories of articles, the abstract does not need to be structured, but should contain important information to recognize the value of the work. Specify five keywords that define the subject of the work. The keywords should be based on the MeSH (Medical Subject Headings) of the National Library of Medicine.

Clinical Trials: at the end of the abstract authors must indicate the registration number of the trial.

3. Text

  1. Original Article: must contain: Introduction, Objective(s), Method(s), Result(s), Discussion, Conclusion(s) and References. The work can have a maximum of 4,000 words (including references), up to seven tables, illustrations and photos and no more than 30 references;
  2. Special Article: must have the same structure as the original articles, but may only be submitted by invitation or inclusion in this category after analysis by the editor;
  3. Review Article: narrative reviews addressing topics of importance to the field. These articles can have up to 5,000 words (including references), up to seven tables, illustrations and photos and a maximum of 60 references;
  4. Update Article: on a topic, method, treatment, etc. It must contain a brief history of the topic, its current state of knowledge and the reasons for the work, study methods (reference sources, selection criteria), hypotheses, study lines, etc. Identical criteria to the review article;
  5. Case Report: must contain an introduction, with a brief review of the literature, a description of the case, important results for diagnosis, evolution, discussion, conclusion and references. It can have a maximum of 1,800 words, up to two tables, illustrations and photos, 10 references and a maximum of four authors;
  6. Letter to the Editor: maximum of 1000 words (including references), with a maximum of two illustrations;
  7. Imaging in Clinical Hematology: maximum of 100 words and three references;
  8. Scientific Comment: this contribution will only be accepted upon invitation from the Editor, who will provide information on its required structure.

4. Acknowledgements

This section is intended to recognize collaborators who contributed significantly but do not warrant authorship, including those who provided financial support or technical assistance for the preparation of the work.

5. Authorship:

All authors must have made substantial contributions to all of the following: (1) conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) writing the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Hematology, Transfusion and Cell Therapy (HTCT) encourages transparency about the contributions of authors, for example, in the form of a CRediT author statement.

 

 

Digital Assets

 

Illustrations and photographs: must have at least 1000 dpi resolution. Color figures must be in CMYK; they must be in TIFF, JPG or CDR format. Do not insert figures within the text. Send them separately.

Tables: Tables must be numbered consecutively, with Arabic numerals and cited in the text in numerical order. If the table requires special symbols, it must be sent as an image in a TIFF or JPG file, in high resolution.

 

 

Citations and References

 

Citations must be numerical and references must be inserted in the order in which they appear in the text.

The Vancouver Style must be used:

  • Authors: List the first six authors followed by ‘et al.’ to indicate that there are more authors.
  • Article Title: The full title of the article.
  • Journal Title: The abbreviated name of the journal in italics.
  • Year: The year of publication.
  • Volume: The volume and issue number of the journal.
  • Start-End Page: The pages where the article can be found

Examples of references

Printed documents

Jornal articles: Padley DJ, Dietz AB, Gastineau DA. Sterility testing of hematopoietic progenitor cell products: a single-institution series of culture-positive rates and successful infusion of culture-positive products. Transfusion. 2007; 47(4):636-43.

Books: Chalmers J. Clinician’s manual on blood pressure and stroke prevention. 3rd ed. London: Science Press; 2002. 70 p.

Richardson MD, Warnock DW. Fungal Infection Diagnosis and Management. 2nd ed. Oxford: Blackwell Science Ltd Editorial Offices; 1997.249 p.

Book chapters: F. Reyes. Lymphocyte differentiation. In P Solal-Céligny, N Brousse, F Reyes, C Gisselbrecht, B Coiffier. Non-Hodgkin`s Lymphomas. Paris: Éditions Frison-Roche; 1993. p.19-29.

Proceedings: Souza AM, Vaz RS, Carvalho MB, Arai Y, Hamerschilak N. Prevalência de testes sorológicos relacionados à hepatitis B e não-A, não-B em doadores de sangue. In: 19º Congresso Brasileiro de Hematologia e Hemoterapia / 26º Congresso da Sociedade Brasileira de Hematologia e Hemoterapia; 2003 Ago 6-9; São Paulo, 2003. Anais. p.103.

Theses: Sandes AF. Caracterização imunofenotípica da diferenciação eritrocitária, granulocítica e megacariótica em pacientes com síndromes mielodisplásicas [tese]. São Paulo: Universidade Federal de São Paulo; 2009. 126p.

Digital documents:

Journal articles: Almeida ID, Coitinho AS, Juckowsky CA, Schmalfuss T, Balsan AM, Röhsig LM. Controle de esterilidade de produtos de células progenitoras hematopoéticas do sangue periférico. Rev Bras Hematol Hemoter [Internet] 2010 [citado 2010 Jun 10]; 32(1): 23-8. Disponível em: www.scielo.br/pdf/rbhh/v32n1/aop03010.pdf

Books: Walker HK, Hall WD, Hurst JW, editors. Clinical methods. The history, physical, and laboratory examinations. 3rd ed. [Internet]. Boston: Butterworths; 1990. [cited 2010 Jun 10]. Available from: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=cm

Preprints:

Smith JR, Jones LM, Williams KD. Novel insights into the molecular mechanisms of aging [Preprint]. bioRxiv. 2024 [cited 2025 Mar 26]. Available from: https://doi.org/10.1101/2024.03.20.585858

Garcia EF, Rodriguez PL. Quantum entanglement in high-energy physics [Preprint]. arXiv. 2025 [cited 2025 Mar 26]. Available from: arXiv:2503.12345.

 

 

Financing Statement

 

Provide the sources of financial support for the work, including names of sponsors, contract number (if any), along with explanations of the role of these sources.

 

 

Contact

 

To the Editor-in-Chief
Eduardo Magalhães Rego

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
Rua Dr. Diogo de Faria, 775 conj. 133 - Vila Clementino
CEP. 04037-002, São Paulo/SP, Brazil
Telephone: (55 11) 2369-7767
E-mail: htct@abhh.org.br

 

 

location_on
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) R. Dr. Diogo de Faria, 775 cj 133, 04037-002, São Paulo / SP - Brasil - São Paulo - SP - Brazil
E-mail: htct@abhh.org.br
rss_feed Stay informed of issues for this journal through your RSS reader
Accessibility / Report Error